257 related articles for article (PubMed ID: 38260807)
21. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
[TBL] [Abstract][Full Text] [Related]
22. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
[TBL] [Abstract][Full Text] [Related]
23. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
25. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
[TBL] [Abstract][Full Text] [Related]
26. Plasma p-tau181/Aβ
Fowler CJ; Stoops E; Rainey-Smith SR; Vanmechelen E; Vanbrabant J; Dewit N; Mauroo K; Maruff P; Rowe CC; Fripp J; Li QX; Bourgeat P; Collins SJ; Martins RN; Masters CL; Doecke JD
Alzheimers Dement (Amst); 2022; 14(1):e12375. PubMed ID: 36447478
[TBL] [Abstract][Full Text] [Related]
27. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
28. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
[TBL] [Abstract][Full Text] [Related]
30. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
Front Neurol; 2021; 12():695696. PubMed ID: 34557143
[No Abstract] [Full Text] [Related]
31. Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.
Xiao Z; Wu X; Wu W; Yi J; Liang X; Ding S; Zheng L; Luo J; Gu H; Zhao Q; Xu H; Ding D
Alzheimers Res Ther; 2021 Jul; 13(1):123. PubMed ID: 34225797
[TBL] [Abstract][Full Text] [Related]
32. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
[TBL] [Abstract][Full Text] [Related]
33. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
34. The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia.
Jungwirth S; Zehetmayer S; Hinterberger M; Tragl KH; Fischer P
Int Psychogeriatr; 2012 Jun; 24(6):959-66. PubMed ID: 22300486
[TBL] [Abstract][Full Text] [Related]
35. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR
Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507
[TBL] [Abstract][Full Text] [Related]
37. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy.
Wang ZB; Tan L; Wang HF; Chen SD; Fu Y; Gao PY; Ma YH; Guo Y; Hou JH; Zhang DD; Yu JT;
Alzheimers Dement; 2023 Aug; 19(8):3613-3624. PubMed ID: 36840620
[TBL] [Abstract][Full Text] [Related]
38. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
39. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
40. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies.
Hamilton CA; O'Brien J; Heslegrave A; Laban R; Donaghy P; Durcan R; Lawley S; Barnett N; Roberts G; Firbank M; Taylor JP; Zetterberg H; Thomas A
Psychol Med; 2023 Dec; 53(16):7865-7873. PubMed ID: 37489795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
